-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GaMFm2r6JOXoW5bNGMkD7IGVJe8n9Z9mgvd2hbQhlNbunSJYMcJsQp5wwjGsppK+ oXRlUVlLXFRu/b4lT/aGng== 0001210437-04-000004.txt : 20040402 0001210437-04-000004.hdr.sgml : 20040402 20040402095319 ACCESSION NUMBER: 0001210437-04-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040331 FILED AS OF DATE: 20040402 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TENDLER DAVID CENTRAL INDEX KEY: 0001210437 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 04711521 MAIL ADDRESS: STREET 1: 120 EAST END AVE CITY: NEW YORK STATE: NY ZIP: 10028 4 1 edgar.xml PRIMARY DOCUMENT X0201 4 2004-03-31 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001210437 TENDLER DAVID 120 EAST END AVENUE APT 4B NEW YORK NY 10028 1 0 0 0 Common stock, $.01 par value per share 2004-03-31 4 A 0 652 3.83 A 15579 D Options to purchase common stock, $.01 par value per share 3.83 2004-03-31 4 A 0 5000 3.83 A 2005-03-31 2014-03-31 Common stock, $.01 par value per share 5000 102500 D These shares were granted pursuant to the Company's Stock Compensation Plan for Outside Directors, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $2,500, until he is no longer an Outside Director. On March 31, 2004, the fair market value of the Common Stock, based on the closing price, was $3.83. These options will become fully vested and immediately exercisable on 03/31/2005. David Tendler 2004-04-02 -----END PRIVACY-ENHANCED MESSAGE-----